ABT stock registered a 52-week high
On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close. The stock registered a 52-week high of $74.15 on October 1. Throughout the week, it’s fallen ~1.6%.
Abbott Laboratories reported its 52-week low of $53.61 on November 1, 2017. Currently, the stock is trading ~5.6% higher than its 50-day moving average of $68.04 and ~13.6% higher than its 200-day moving average of $63.20.
Year-to-date, ABT stock has registered a rise of 26%. Over the last month, Abbott Laboratories has returned ~7%, and it’s risen ~32% over the last 12 months. Peers Medtronic (MDT), Boston Scientific (BSX), and Baxter International (BAX) have registered returns of 23.3%, 30%, and 18%, respectively, over the past year.
Recent events affecting ABT
On October 1, Abbott Laboratories received the CE mark for its Freestyle Libre 2 with an optional real-time alarm. The stock registered a rise in price and reported a 52-week high during the day.
On September 28, Wells Fargo raised its target price on ABT stock from $80 to $83. The stock rose ~0.47% on the day.
On September 27, Abbott Laboratories received the CE mark for its first troponin test, which was developed to predict the possibility of a heart attack in healthy adults. The stock rose ~0.25% on the day.
Also in September, the company posted positive data on its Portico TAVR (transcatheter aortic valve replacement) device and Mitraclip. Both events triggered a stock price rise.